Biotech Startup Challenges Ban on Gene-Edited Embryos

In a secure laboratory in New York City, Cathy Tie, founder and CEO of Origin Genomics, revealed a cryogenic storage unit containing frozen human embryos. These embryos, donated by families burdened by generations of life-threatening genetic disorders, carry mutations for conditions such as Huntington’s disease, cystic fibrosis, and Tay-Sachs. Tie is using them to test proprietary gene-editing technologies designed to repair these defects before birth, a move that could prevent diseases from being passed to future generations.

Despite the therapeutic potential, Tie acknowledges that creating gene-edited babies remains illegal in the United States. However, she contends that the current prohibition may be outdated. “Hundreds of millions of people around the world have these diseases,” Tie said. “What we are proposing is something completely revolutionary: apply this amazing precision genome editing to embryos that have a mutation before they are born.” She argues that the benefits of eradicating these hereditary conditions outweigh the risks, potentially changing the entire paradigm of medicine.

Origin is not working with CRISPR alone but is utilizing newer, more precise techniques such as prime editing and base editing, some developed with the aid of artificial intelligence. The company is also testing its tools on induced pluripotent stem cells and fibroblasts derived from adult skin or blood, including cells carrying mutations linked to breast cancer. Under microscopic examination, successful delivery of the gene editors is indicated by fluorescent green glowing cells, marking the initial stage of correcting genetic errors.

The resurgence of interest in human embryo editing follows the 2018 scandal involving Chinese scientist He Jiankui, who was imprisoned for three years after announcing the birth of the first genetically modified babies. That experiment was widely condemned as premature and unsafe due to the risk of unintended mutations. Today, while technology has improved, significant ethical and safety concerns persist among scientists and bioethicists.

Robin Lovell-Badge of the Francis Crick Institute warned that companies like Origin may be giving false hope to patients and rushing ahead without sufficient caution. “I am concerned that they are rushing ahead too fast and making some mistake,” Lovell-Badge said, fearing that failure could set the entire field back. Others worry about the slippery slope toward “designer babies.” Katie Hasson, who leads the Center for Genetics and Society, criticized the vision of some Silicon Valley investors for promoting mass-produced, genetically engineered humans.

Additionally, there are fears that U.S. regulations could drive experimentation to countries with looser oversight, a phenomenon known as “genome-editing tourism,” according to R. Alta Charo of the University of Wisconsin-Madison. Tie addressed scrutiny regarding her past association with He Jiankui, stating he has no involvement with Origin and emphasizing her commitment to safety, independent oversight, and transparency.

Tie hopes that Origin will generate enough evidence to persuade Congress and international regulators to lift restrictions on FDA consideration of gene-edited embryo experiments. “I think that if you have a technology that can be proven to be safe… it is unethical to not pursue this research,” she said. “My hope is that humanity can capture the upside of this technology.”